Guidelines for Osteoprotection in Breast Cancer Patients on an Aromatase Inhibitor

Breast Care

Volumn 5, Issue 5, 2010, Pages 290-296

  Hadji, Peyman ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Aromatase inhibitors; Bone loss; Bone mineral density; Breast cancer; Fracture

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; EXEMESTANE; GONADORELIN AGONIST; IBANDRONIC ACID; LETROZOLE; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER TREATMENT INDUCED BONE LOSS; CANCER TREATMENT RELATED BONE LOS; CANCER TREATMENT RELATED BONE LOSS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG INDUCED DISEASE; FEMALE; FRACTURE; HORMONAL THERAPY; HUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

EID: 78049359494     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000321426     Document Type: Review

References (68)

1. Clunie GP, Clark A, Mortimer CJ, Stephenson S, Aitken J, Smith C, Sherwin E, Archer TJ: Evaluat-ing bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors. Eur J Surg Oncol 2009;35:475-80.
2. Hadji P: Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from post-menopausal osteoporosis. Crit Rev Oncol Hematol 2009;69:73-82.
3. Folkestad L, Bjarnason NH, Bjerregaard JK, Brixen K: The effect of aromatase inhibitors on bone metabolism. Basic Clin Pharmacol Toxicol 2008;104:3-10.
4. Miller WR, Bartlett J, Brodie AMH, Breuggemeier RW, Di Salle E, Lonning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE: Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829-37.
5. Janni W, Hepp P: Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010;36:249-61.
6. Conte P, Frassoldati A: Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety into per-spective. Breast J 2007;13:28-35.
7. Ozair S, Iqbal S: Efficacy and safety of aromatase inhibitors in early breast cancer. Expert Opin Drug Saf 2008;7:547-58.
8. Macedo LF, Sabnis G, Brodie A: Aromatase in-hibitors and breast cancer. Ann N Y Acad Sci 2009;1155:162-73.
9. Geisler J. Aromatase inhibitors: from bench to bedside and back. Breast Cancer 2008;15:17-26.
10. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE: Influence of anastrozole (Arimidex), a selec-tive, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
11. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
12. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7.
13. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE: In vivo measurement of aro-matase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
14. Howell A, Cuzick J, Baum M, et al.; ATAC Trialists' Group: Results of the ATAC (Arimi-dex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
15. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collabora-tive Group: A comparison of letrozole and tamoxi-fen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
16. Coates AS, Keshaviah A, Thurlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98. J Clin Oncol 2007;25:486-92.
17. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mau-riac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS; BIG 1-98 Collaborative Group: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76.
18. Boccardo R, Rubagotti A, Puntoni M, et al.: Switching to anastrozole versus continued tamoxi-fen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-47.
19. Coombes RC, Hall E, Gibson LJ, et al.: Intergroup Exemestane Study. A randomized trial of exemes-tane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92;
20. Erratum N Engl J Med 2004;351:2461.
21. Coombes RC, Kilburn LS, Snowdon CF, et al.: Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559-570;
22. Erratum Lancet 2007;369:906.
23. Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett MJS, van de Velde CJH: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant mul-tinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 2009;69(suppl 2):67s(abstr 15).
24. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P: Clini-cal perspectives on the utility of aromatase inhibi-tors for the adjuvant treatment of breast cancer. Breast 2009;18(suppl 2):S1-11.
25. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
26. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, Wilson CR, Angerson WJ, Doughty JC: Patterns and predictors of early recurrence in postmenopausal women with estro-gen receptor-positive early breast cancer. Breast Cancer Res Treat 2009;117:91-8.
27. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R: Breast cancer recurrence and re-lated mortality in US pts with early breast cancer. J Clin Oncol 2005;23:62s(abstr 738).
28. Baum M, Buzdar A, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
29. Goss PE, Ingle JN, Martino S, Robert NJ, et al.: Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
30. Jakesz, R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: com-bined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
31. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008a;9:45-53.
32. Jonat W, Hilpert F, Kaufmann M: Aromatase inhi-bitiors: a safety comparison. Expert Opin Drug Saf 2007;6:165-74.
33. Hadji P, Body JJ, Aapro MS, Brufsky A, Cole-man RE, Guise T, Lipton A, Tubiana-Hulin M: Practical guidance for the management of aroma-tase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-16.
34. Hadji P, Ziller M, Kieback DG, et al.: Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicen-tre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009;20:1203-9.
35. Delaney MF: Strategies for the prevention and treatment of osteoporosis during early post-menopause. Am J Obstet Gynecol 2006;194(2 suppl):S12-23. Review.
36. Gibson K, O'Bryant CL: Screening and manage-ment of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract 2008;14:139-45.
37. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH; NCCN Task Force Report: Bone Health in Cancer Care: J Natl Compr Canc Netw 2009;7(suppl 3):S1-S32; quiz S33-S35.
38. Geisler J, Lonning PE: Impact of aromatase inhi-bitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 2010;118:294-9.
39. Bertoldo F, Pancheri S, Zenari S, Boldini S: Emerging drugs for the management of cancer treatment induced bone loss. Expert Opin Emerg-ing Drugs 2010;15:323-42. Review.
40. Yamamoto DS, Hallquist Viale P: Update on iden-tifying and managing osteoporosis in women with breast cancer. Clin J Oncol Nurs 2009;13:E18-E29.
41. Rugo HS: The breast cancer continuum in hor-mone-receptor-positive breast cancer in postmeno-pausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008;19:16-27.
42. Eastell R, Hannon RA, Cuzick J, et al.: Effect of anastrozole on bone density and bone turn over: results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study. J Bone Miner Res 2002;17(suppl 1):S165.
43. Gnant M, Hausmaninger H, Samonigg H: Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+/-zole-dronate as adjuvant treatment for hormone recep-tor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast Cancer Res Treat 2002;76(suppl 1):S31(abstr 12).
44. McCaig FM, Renshaw, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM: A randomized study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover. Cancer Res 2009;69(suppl 2):148s-149s(abstr 1145).
45. McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Eastell R: Interaction between body mass index and bone turnover during aromatase in-hibition: evidence from the letrozole (L), exemes-tane (E), and anastrozole (A) pharmacodynamics (LEAP) trial. J Clin Oncol 2007;25(18S):17S(abstr 560).
46. Reid DM: Prevention of osteoporosis after breast cancer. Mat̀ItaS 2009;64:4-8.
47. Coleman RE, Body JJ, Gralow JR, Lipton A: Bone loss in patients with breast cancer receiving aroma-tase inhibitors and associated treatment strategies. Cancer Treat Rev 2008;34(suppl 1):S31-42.
48. Bundred NJ: Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol 2009;21:60-7.
49. Abdulhaq H, Geyer C: Safety of adjuvant endo-crine therapy in postmenopausal women with breast cancer. Am J Clin Oncol 2008;31:595-605.
50. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group: Effect of an aromatase inhibitor on BMD and bone turn-over markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (182332030). J Bone Miner Res 2006;21:1215-23.
51. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gel-ber RD, Goldhirsch A, Coates AS; BIG 1-98 Col-laborative and International Breast Cancer Study Groups: Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxi-fen in the BIG 1-98 trial. Ann Oncol 2009;20:1489-98.
52. Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast can-cer participating in the Intergroup Exemestane Study(IES): a randomized controlled study. Lancet Oncol 2007;8:119-27.
53. Hadji P, Ziller M, Kieback DG, et al.: The effect of exemestane or tamoxifen on markers of bone turn-over: results of a German sub-study of the Tamoxi-fen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009a;18:159-64.
54. Pant S, Shapiro CL: Aromatase inhibitor-asso-ciated bone loss: clinical considerations. Drugs 2008;68:2591-600.
55. Yamamoto Y, Iwase H: Safety profiles of aroma-tase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol 2008;13:384-94.
56. Hillner BE, Ingle JN, Chlebowski RT, et al.: Amer-ican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health is-sues in women with breast cancer. J Clin Oncol 2003;21:4042-57.
57. Cummings SR, Nevitt MC, Browner WS, et al.: Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
58. National Osteoporosis Foundation: Physician's Guide: Pharmacologic Options. www.nof.org/physguide/pharmacologic.htm; accessed October 4, 2007.
59. World Health Organization: Technical Report Series 921: Prevention and Management Osteo-porosis. Geneva, WHO; 2003 pp. 1-192.
60. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AHG, Rizzoli R, Saad F, Thurlimann B: Guidance on the use of bisphosphonates in solid tumours: recommenda-tions of an international expert panel. Ann Oncol 2008;19:420-32.
61. Hadji P, Ziller M, Albert US, Kalder M: Assess-ment of fracture risk in women with breast cancer using current vs. emerging guidelines. Br J Cancer 2010;102:645-50.
62. Saarto T, Vehmanen L, Elomaa I, et al.: The effect of clodronate and antioestrogens on bone loss as-sociated with oestrogen withdrawal in postmeno-pausal women with breast cancer. Br J Cancer 2001;84:1047-51.
63. Greenspan SL, Brufsky A, Lembersky BC, et al.: Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644-52.
64. Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, Jin L, Warsi GM, Ericson SG, Perez EA: Zoledronic acid ef-fectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85.
65. Brufsky A, Harker WG, Beck JT, Carroll R, Jin L, Warsi G Argonza-Aviles E, Ericson SG, Perez EA; Z-FAST Study Group: The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. 32nd Annual San Antonio Breast Cancer Symposium, San An-tonio, TX, USA; December 9-13, 2009; abstr 4083.
66. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE: Effective inhibition of aromatase inhibitor-asso-ciated bone loss by zoledronic acid in postmeno-pausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Can-cer 2008;112:1001-10.
67. Van Poznak C, Hannon RA, Mackey JR, et al.: Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967-75.
68. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010. Epub ahead of print.